Clinical Trials Browser

Phase 2 × Dasatinib × Thoracic × Clear all

NCT04284202 2020-02-25

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00459342 2019-03-05

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00509041 2016-08-11

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2 Completed

46 enrolled 14 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00570401 2016-01-22

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Phase 2 Completed

22 enrolled 6 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00470054 2015-05-05

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 10 charts

Small Cell Lung Carcinoma

NCT00564876 2015-02-23

TOP0706

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01491633 2014-07-15

Dasatinib in Advanced Squamous Cell Lung Cancer

Phase 2 Terminated

5 enrolled 7 charts

Lung Neoplasms

NCT00858403 2014-01-15

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Phase 2 Terminated

7 enrolled 7 charts

Lung Neoplasms